A recent study that sought to characterize the structure and genetic features of HIV-1 antibodies from vaccinated rhesus macaques isolated four identical neutralizing antibody (nAb) lineages across multiple animals.
MHRP last week launched a Phase 2 clinical trial in Thailand to evaluate an interleukin-15 (IL-15) superagonist, ImmunityBio’s Anktiva®, administered during acute HIV infection as an experimental therapy to target establishment of the HIV reservoir at a very early stage.
